A review of perioperative statin therapy for noncardiac surgery

Sara Skrlin, Vivian Hou

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The leading cause of perioperative morbidity and mortality after major noncardiac surgery is cardiovascular complications. Clinical trials of lipid-lowering 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) have shown improved cardiovascular outcomes; therefore, statins have become a mainstay in the prevention of cardiovascular disease. Retrospective trials and a small number of prospective randomized trials indicate that statin use may be beneficial during the perioperative period. In addition to the effects on serum lipid levels, statins influence inflammatory, thrombotic, and vasodilatory cellular pathways; and thus, their beneficial effects are not limited to patients with hypercholesterolemia. This review will (1) examine the evidence for using perioperative statin therapy in the noncardiac surgical patient (2) explore the possible consequences of statin withdrawal, and (3) revisit the evidence for the safety of statin use. Further studies are still needed to establish the optimal dosage as well as timing and length of statin therapy perioperatively.

Original languageEnglish (US)
Pages (from-to)283-290
Number of pages8
JournalSeminars in Cardiothoracic and Vascular Anesthesia
Volume14
Issue number4
DOIs
StatePublished - Dec 2010

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Therapeutics
Lipids
Perioperative Period
Hypercholesterolemia
Oxidoreductases
Cardiovascular Diseases
Clinical Trials
Morbidity
Safety
Mortality

Keywords

  • HMG-CoA reductase inhibitors
  • perioperative period
  • statins
  • surgery

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

A review of perioperative statin therapy for noncardiac surgery. / Skrlin, Sara; Hou, Vivian.

In: Seminars in Cardiothoracic and Vascular Anesthesia, Vol. 14, No. 4, 12.2010, p. 283-290.

Research output: Contribution to journalArticle

@article{029976781e8346d8a03cd9b6d7d9d2dd,
title = "A review of perioperative statin therapy for noncardiac surgery",
abstract = "The leading cause of perioperative morbidity and mortality after major noncardiac surgery is cardiovascular complications. Clinical trials of lipid-lowering 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) have shown improved cardiovascular outcomes; therefore, statins have become a mainstay in the prevention of cardiovascular disease. Retrospective trials and a small number of prospective randomized trials indicate that statin use may be beneficial during the perioperative period. In addition to the effects on serum lipid levels, statins influence inflammatory, thrombotic, and vasodilatory cellular pathways; and thus, their beneficial effects are not limited to patients with hypercholesterolemia. This review will (1) examine the evidence for using perioperative statin therapy in the noncardiac surgical patient (2) explore the possible consequences of statin withdrawal, and (3) revisit the evidence for the safety of statin use. Further studies are still needed to establish the optimal dosage as well as timing and length of statin therapy perioperatively.",
keywords = "HMG-CoA reductase inhibitors, perioperative period, statins, surgery",
author = "Sara Skrlin and Vivian Hou",
year = "2010",
month = "12",
doi = "10.1177/1089253210386387",
language = "English (US)",
volume = "14",
pages = "283--290",
journal = "Seminars in Cardiothoracic and Vascular Anesthesia",
issn = "1089-2532",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - A review of perioperative statin therapy for noncardiac surgery

AU - Skrlin, Sara

AU - Hou, Vivian

PY - 2010/12

Y1 - 2010/12

N2 - The leading cause of perioperative morbidity and mortality after major noncardiac surgery is cardiovascular complications. Clinical trials of lipid-lowering 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) have shown improved cardiovascular outcomes; therefore, statins have become a mainstay in the prevention of cardiovascular disease. Retrospective trials and a small number of prospective randomized trials indicate that statin use may be beneficial during the perioperative period. In addition to the effects on serum lipid levels, statins influence inflammatory, thrombotic, and vasodilatory cellular pathways; and thus, their beneficial effects are not limited to patients with hypercholesterolemia. This review will (1) examine the evidence for using perioperative statin therapy in the noncardiac surgical patient (2) explore the possible consequences of statin withdrawal, and (3) revisit the evidence for the safety of statin use. Further studies are still needed to establish the optimal dosage as well as timing and length of statin therapy perioperatively.

AB - The leading cause of perioperative morbidity and mortality after major noncardiac surgery is cardiovascular complications. Clinical trials of lipid-lowering 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) have shown improved cardiovascular outcomes; therefore, statins have become a mainstay in the prevention of cardiovascular disease. Retrospective trials and a small number of prospective randomized trials indicate that statin use may be beneficial during the perioperative period. In addition to the effects on serum lipid levels, statins influence inflammatory, thrombotic, and vasodilatory cellular pathways; and thus, their beneficial effects are not limited to patients with hypercholesterolemia. This review will (1) examine the evidence for using perioperative statin therapy in the noncardiac surgical patient (2) explore the possible consequences of statin withdrawal, and (3) revisit the evidence for the safety of statin use. Further studies are still needed to establish the optimal dosage as well as timing and length of statin therapy perioperatively.

KW - HMG-CoA reductase inhibitors

KW - perioperative period

KW - statins

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=78650822277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650822277&partnerID=8YFLogxK

U2 - 10.1177/1089253210386387

DO - 10.1177/1089253210386387

M3 - Article

C2 - 21041202

AN - SCOPUS:78650822277

VL - 14

SP - 283

EP - 290

JO - Seminars in Cardiothoracic and Vascular Anesthesia

JF - Seminars in Cardiothoracic and Vascular Anesthesia

SN - 1089-2532

IS - 4

ER -